Witch hunt against tumor cells enhanced by dendritic cells

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Conventional cancer treatments primarily focus on direct tumor cell elimination.
• Emerging evidence highlights the role of radiotherapy and chemotherapy in stimulating anti-tumor immune responses.
• These immune responses significantly contribute to the overall therapeutic efficacy.

Purpose of the Study:

• To review the molecular mechanisms underlying radiation and chemotherapy-induced anti-tumor immune responses.
• To discuss the clinical implications of these mechanisms for predicting and improving treatment success.

Main Methods:

• Review of existing scientific literature on tumor-intrinsic changes affecting immune responses.
• Analysis of molecular pathways involving calreticulin and high-mobility group box 1 protein.
• Discussion of the role of dendritic cells and T lymphocytes in anti-tumor immunity.

Main Results:

• Two key tumor-intrinsic changes identified: calreticulin translocation and high-mobility group box 1 (HMGB1) release.
• These changes enhance the engulfment and processing of apoptotic tumor cells by dendritic cells.
• This process facilitates the cross-priming of tumor-specific T lymphocytes, crucial for anti-tumor immunity.

Conclusions:

• Calreticulin exposure and HMGB1 release are critical mediators of the anti-tumor immune response elicited by radio/chemotherapy.
• Understanding these mechanisms can lead to strategies for predicting patient response to therapy.
• Clinical exploitation of these pathways may enhance the efficacy of chemo/radiotherapy by boosting anti-tumor immunity.